A biophysical assay targeting SARS CoV-2 RNA
针对 SARS CoV-2 RNA 的生物物理检测
基本信息
- 批准号:10381446
- 负责人:
- 金额:$ 29.99万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-06-27 至 2024-05-31
- 项目状态:已结题
- 来源:
- 关键词:2019-nCoV5&apos Untranslated RegionsAddressAffectAffinityAmino SugarsAntisense OligonucleotidesAntiviral AgentsAwarenessBacterial GenesBindingBiological AssayBiophysicsCOVID-19COVID-19 pandemicCOVID-19 treatmentCaringCell Culture TechniquesCessation of lifeChemicalsChemistryCommunicationCommunitiesComplexCongestiveCoughingCountryDevelopmentDiseaseDrug DesignElementsEmploymentEventExposure toFirefly LuciferasesFluorescenceFluorescent ProbesFutureGenesGenetic TranscriptionGenomeGovernmentGrantHandwashingHealthHealth StatusHealthcare SystemsHigh Pressure Liquid ChromatographyHumanIn VitroIndividualInfectionInfection preventionInterruptionLaboratoriesLeadLegal patentLibrariesLifeLigand BindingLigandsMasksMedicalMental HealthMessenger RNAModelingNational Institute of Allergy and Infectious DiseaseNucleic AcidsPersonsPhasePopulationProteinsProteomePublic HealthQuarantineRNARNA BindingRNA SequencesRNA VirusesRNA libraryRNA replicationRapid screeningReporter GenesResourcesRespiratory distressReverse TranscriptionRibonucleic Acid Regulatory SequencesRiskRoleSARS coronavirusSARS-CoV-2 infectionSchoolsScientistServicesSevere Acute Respiratory SyndromeSmall Business Innovation Research GrantSmall Business Technology Transfer ResearchSocial DistanceSolidSpanish fluStructureTechnologyTennesseeTherapeuticTransactivationTranscriptTranslationsUniversitiesVaccinationVaccinesValidationViralViral ProteinsVirusVirus ReplicationWorkanalogassay developmentbiophysical analysiscombatcoronavirus diseasedesigndrug developmentexperimental studygenomic RNAhigh throughput screeningimprovedinnovationinterestmicrobialmutantnanomolarnew technologynovelpandemic coronaviruspandemic diseasepandemic influenzaphase 2 studyphosphorodiamidate morpholino oligomerphysical conditioningpreventrespiratoryscreeningsocialstemsuccesssymptom managementsymptom treatmenttechnology developmentvaccine developmentviral RNA
项目摘要
PROJECT SUMMARY
The world is immersed in a health crisis rivaled only by the Spanish flu pandemic of 1918-1919. The difference
between the crisis of today and the crisis a century ago is that we have advanced communication technology
greatly so that huge populations of people around the globe are aware of risks and can take appropriate
precautions, such as the employment of quarantining, isolation, social distancing, and masks and handwashing.
Governments have closed schools and outlawed large social gatherings. Medical care has greatly improved,
and those most affected have received symptomatic treatment in the absence of a cure for CoVID-19. The
problem must be dealt at multiple fronts, such as vaccine development, drug development and new technologies,
assays for mitigating viral effects. The proposed project is significant because it proposes a novel
in vitro biophysical screening assay for a unique and yet untapped RNA structure in SARS-CoV-2
virus, that can be used in the future to generate RNA specific antiviral compounds.
Nucleic acids are promising avenues for drug design, both as therapeutics and as targets. Here we propose an
innovative screening approach for identification of a novel class of ligands that are specific for an RNA
element within the viral RNA genome that is vital for replication of the virus, and we propose a
biophysical screening assay as a first step for identifying such ligands. First, as outlined in Specific Aim
1, we will characterize a model nucleic acid (RNA) domain that will be synthesized, characterized and used to
identify a RNA specific fluorescent probe. The optimized probe will then be used for developing a high-throughput
screening assay for discovery of nanomolar binders to this RNA. The RNA specific high-affinity binders will then
be combined with sequence-specific RNA binding ligands to validate the assay development and its utility. The
mechanism of action will be confirmed using inhibition of firefly luciferase translation in a reporter gene assay
(Specific Aim 2). While the focus of this application, as the needed first step, is on the development and
validation of the biophysical assay for the underlying SARS-CoV-2 RNA structures, a successful validation of
the approach will open the doors for discovery and development of lead compounds for inhibition of SARS-CoV
in Phase II studies. NUBAD and its team of scientists and collaborators is uniquely qualified to perform these
assays and develop the potential leads in Phase II, in addition to providing a template for the scientific community
to use the screening technology for their own discovery platforms. Success of the approach will also allow us to
expand the screening technology to other RNA structures in SARS and other RNA viruses, and provide the
screening resource as a service to the scientific community.
项目总结
世界正沉浸在一场仅次于1918-1919年西班牙流感大流行的健康危机中。区别在于
在今天的危机和一个世纪前的危机之间,我们拥有先进的通信技术
以便全球各地的大量人口意识到风险并采取适当的措施
预防措施,如使用隔离、隔离、社交距离、口罩和洗手。
政府已经关闭了学校,并宣布大型社交集会为非法。医疗服务有了很大的改善,
而受影响最严重的人在新冠肺炎无法治愈的情况下接受了对症治疗。这个
必须在多个方面处理问题,如疫苗开发、药物开发和新技术,
减轻病毒影响的化验。拟议的项目意义重大,因为它提出了一种新颖的
SARS-CoV-2中一种独特但尚未开发的RNA结构的体外生物物理筛选
病毒,将来可以用来产生RNA特异性的抗病毒化合物。
核酸是药物设计的很有前途的途径,既是治疗药物,也是靶点。在这里,我们提出一种
用于识别一类新的RNA特异性配体的创新筛选方法
病毒RNA基因组中对病毒复制至关重要的成分,我们建议一种
生物物理筛选试验是鉴定这类配体的第一步。第一,如《具体目标》中所述
1,我们将表征一个模型核酸(RNA)结构域,该结构域将被合成、表征并用于
鉴定一种RNA特异性荧光探针。然后,优化后的探头将用于开发高通量的
发现与该RNA的纳米分子结合的筛选试验。然后,RNA特异的高亲和力结合物将
与序列特异的RNA结合配体结合,以验证该方法的发展及其实用性。这个
作用机制将通过抑制萤火虫荧光素酶的翻译在报告基因测试中得到证实
(具体目标2)。虽然这个应用程序的重点,作为必要的第一步,是在开发和
对SARS-CoV-2潜在RNA结构的生物物理测试的验证,成功地验证了
该方法将为发现和开发抑制SARS-CoV的先导化合物打开大门
在第二阶段研究中。NUBAD及其科学家和合作者团队是唯一有资格执行这些任务的
除了为科学界提供模板外,还在第二阶段分析和开发潜在的线索
将筛选技术用于他们自己的发现平台。该方法的成功还将使我们能够
将筛选技术扩展到SARS和其他RNA病毒的其他RNA结构,并提供
筛选资源,为科学界提供服务。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
sandra Paige story其他文献
sandra Paige story的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('sandra Paige story', 18)}}的其他基金
A biophysical assay targeting SARS CoV-2 RNA
针对 SARS CoV-2 RNA 的生物物理检测
- 批准号:
10653818 - 财政年份:2022
- 资助金额:
$ 29.99万 - 项目类别:
A biophysical assay targeting an essential bacterial gene
针对重要细菌基因的生物物理测定
- 批准号:
10453726 - 财政年份:2021
- 资助金额:
$ 29.99万 - 项目类别:
A biophysical assay targeting an essential bacterial gene
针对重要细菌基因的生物物理测定
- 批准号:
10324513 - 财政年份:2021
- 资助金额:
$ 29.99万 - 项目类别:
A biophysical assay for RNA based resistance
基于 RNA 的耐药性的生物物理测定
- 批准号:
10220711 - 财政年份:2020
- 资助金额:
$ 29.99万 - 项目类别:
A biophysical assay for RNA based resistance
基于 RNA 的耐药性的生物物理测定
- 批准号:
10080557 - 财政年份:2020
- 资助金额:
$ 29.99万 - 项目类别:
Development of Aminoglycoside-Nucleic Acid Conjugates for Inactivation of an Antibiotic Resistance-Conferring Aminoglycoside Sensing Riboswitch
氨基糖苷-核酸缀合物的开发用于灭活赋予抗生素抗性的氨基糖苷传感核糖开关
- 批准号:
9015742 - 财政年份:2015
- 资助金额:
$ 29.99万 - 项目类别:
相似国自然基金
晚期妊娠维持和抑制早产中cAMP信号活化PR的作用机制研究
- 批准号:81300507
- 批准年份:2013
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
相似海外基金
P1082 - Revealing Mercer 5's Pulsar Population with Parkes
P1082 - 揭秘默瑟 5
- 批准号:
Local : csiro:P1082 - 财政年份:
- 资助金额:
$ 29.99万 - 项目类别:














{{item.name}}会员




